Sacituzumab tirumotecan for recurrent or metastatic salivary gland or thyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a new drug called sacituzumab tirumotecan for people with recurrent or metastatic adenoid cystic carcinoma or papillary thyroid carcinoma. The drug works by targeting a protein on cancer cells to deliver treatment directly, which may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adenoid cystic carcinoma or papillary thyroid carcinoma that is locally advanced, recurrent, or has spread to other parts of the body.
- You are 18 years or older (21 in Singapore).
- You are fully active or able to do light work.
- You have not received more than one prior line of therapy for your cancer type (for papillary thyroid carcinoma, you must have had at least one prior line).
- You have not been treated with certain types of targeted therapy (TROP2-directed ADC or topoisomerase I inhibitor).
- You have not had major surgery, radiation, or other cancer treatment within a specific time before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called sacituzumab tirumotecan for thymic carcinoma that has spread or come back after prior treatment. The goal is to see if this drug can help shrink or control the cancer.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
This trial tests a combination of a targeted antibody-drug and focused radiation for people with advanced or recurrent salivary gland cancer that has spread. It aims to see if this treatment can help control the disease when standard treatments have stopped working.
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
This study tests a new drug called sacituzumab tirumotecan for people with advanced thymus tumors that have already been treated once. The drug is given as an infusion and may help control the tumor.
Hear when a new Recurrent Adenoid Cystic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.